Skip to main content
SpringerLink
Log in

Irisin and Visfatin Predicts Severity of Diabetic Nephropathy

  • Original Research Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Although the roles of irisin and visfatin have been well established in diabetes mellitus, there are limited studies about their association in diabetic nephropathy. The present study was designed to assess the levels of irisin and visfatin and their association with the severity of diabetic nephropathy. 43 diabetic nephropathy cases and 43 diabetic subjects without nephropathy were enrolled in the study. Serum levels of irisin and visfatin were compared in both the groups. Irisin and visfatin were significantly increased in diabetic nephropathy cases when compared with diabetes subjects without nephropathy. eGFR was negatively correlated with visfatin (r = −0.323, p = 0.034), irisin (r = −0.324, p = 0.034), urine albumin (r = −0.443, p = 0.003) and albumin creatinine ratio (r = −0.419, p = 0.005) in patients with diabetic nephropathy. Visfatin was significantly elevated in stage IV nephropathy compared with stage III nephropathy. We conclude that irisin and visfatin are elevated in diabetic nephropathy and can be an index of its severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ESRD:

End stage renal disease

GFR:

Glomerular filtration rate

CKD:

Chronic kidney disease

ACR:

Albumin creatinine ratio

References

  1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–76.

    Article  PubMed  Google Scholar 

  2. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy—a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc. 2004;96(11):1445.

    PubMed  PubMed Central  Google Scholar 

  3. Unnikrishnan R, Rema M, Pradeepa R, Deepa M, Shanthirani CS, Deepa R, et al. Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45). Diabetes Care. 2007;30(8):2019–24.

    Article  CAS  PubMed  Google Scholar 

  4. Gurel A, Atli H, Duzenci D, Aydin S, Dogukan A. Plasma and saliva irisin levels of patients with diabetic nephropathy and non-diabetic proteinuria. Turk Nephrol Dial Transplant. 2015;24(3):302–6.

    Article  Google Scholar 

  5. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98:769–78.

    Article  CAS  Google Scholar 

  6. Xin C, Liu J, Zhang J, Zhu D, Wang H, Xiong L, et al. Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obes. 2016;40(3):443–51.

    Article  CAS  Google Scholar 

  7. Espes D, Lau J, Carlsson PO. Increased levels of irisin in people with long-standing Type 1 diabetes. Diabet Med J Br Diabet Assoc. 2015;32(9):1172–6.

    Article  CAS  Google Scholar 

  8. García-Fontana B, Reyes-García R, Morales-Santana S, Ávila-Rubio V, Muñoz-Garach A, Rozas-Moreno P, et al. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state? Endocrine. 2016;52(1):54–62.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang C, Ding Z, Lv G, Li J, Zhou P, Zhang J. Lower irisin level in patients with type 2 diabetes mellitus: a case–control study and meta-analysis. J Diabetes. 2016;8(1):56–62.

    Article  CAS  PubMed  Google Scholar 

  10. Belviranli M, Okudan N, Çelik F. Association of circulating irisin with insulin resistance and oxidative stress in obese women. Horm Metab Res. 2016;48(10):653–7.

    Article  CAS  PubMed  Google Scholar 

  11. Huh JH, Ahn SV, Choi JH, Koh SB, Chung CH. High serum irisin level as an independent predictor of diabetes mellitus: a longitudinal population-based study. Medicine (Baltimore). 2016;95(23):e3742.

    Article  CAS  Google Scholar 

  12. Kang YS, Cha DR. The role of visfatin in diabetic nephropathy. Chonnam Med J. 2011;47:139–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M, et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia. 2007;50:1033–7.

    Article  CAS  PubMed  Google Scholar 

  14. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91:295–9.

    Article  CAS  PubMed  Google Scholar 

  15. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2008;23:959–65.

    Article  CAS  PubMed  Google Scholar 

  16. Kanga YS, Lee MH, Songa HK, Kima JU, Gheea JY, Chaa JJ, et al. Chronic administration of visfatin ameliorated diabetic nephropathy in type 2 diabetic mice. Kidney Blood Press Res. 2016;41:311–24.

    Article  CAS  Google Scholar 

  17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Qiu S, Cai X, Yin H, Zügel M, Sun Z, Steinacker JM, et al. Association between circulating irisin and insulin resistance in non-diabetic adults: a meta-analysis. Metabolism. 2016;65(6):825–34.

    Article  CAS  PubMed  Google Scholar 

  19. Wang H, Zhang X, Chen W, Huang Q, Chen Q. Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes. J Diabetes Complicat. 2015;29(3):384–9.

    Article  PubMed  Google Scholar 

  20. Shelbaya S, Abushady MM, Nasr MS, Bekhet MM, Mageed YA, Abbas M. Study of irisin hormone level in type 2 diabetic patients and patients with diabetic nephropathy. Curr Diabetes Rev. 2017. https://doi.org/10.2174/1573399813666170829163442.

    Article  Google Scholar 

  21. Khidr EG, Ali SS, Elshafey MM, Fawzy OA. Association of irisin and FNDC5 rs16835198 G > T gene polymorphism with type 2 diabetes mellitus and diabetic nephropathy. An Egyptian pilot study. Gene. 2017;626:26–31.

    Article  CAS  PubMed  Google Scholar 

  22. Liu J-J, Liu S, Wong MDS, Tan CSH, Tavintharan S, Sum CF, et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complicat. 2014;28(2):208–13.

    Article  PubMed  Google Scholar 

  23. Ebert T, Focke D, Petroff D, Wurst U, Richter J, Bachmann A, et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol. 2014;170(4):501–6.

    Article  CAS  PubMed  Google Scholar 

  24. Hu W, Wang R, Li J, Zhang J, Wang W. Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy. Ann Clin Biochem. 2016;53(Pt 1):67–74.

    Article  CAS  PubMed  Google Scholar 

  25. Kang YS, Song HK, Lee MH, Ko GJ, Han JY, Han SY, et al. Visfatin is upregulated in type-2 diabetic rats and targets renal cells. Kidney Int. 2010;78:170–81.

    Article  CAS  PubMed  Google Scholar 

  26. El Samahi MH, Ismail NA, Matter RM, Selim A, Ibrahim AA, Nabih W. Study of visfatin level in type 1 diabetic children and adolescents. Open Access Maced J Med Sci. 2017;5(3):299–304.

    PubMed  PubMed Central  Google Scholar 

  27. Kang YS, Lee MH, Song HK, Kim JE, Ghee JY, Cha JJ, et al. Chronic administration of visfatin ameliorated diabetic nephropathy in type 2 diabetic mice. Kidney Blood Press Res. 2016;41(3):311–24.

    Article  CAS  PubMed  Google Scholar 

  28. Rodrigues KF, Pietrani NT, Bosco AA, Ferreira CN, Sandrim VC, Gomes KB. Visfatin levels are decreased in advanced stages of diabetic nephropathy. Ren Fail. 2015;37(9):1529–30.

    Article  CAS  PubMed  Google Scholar 

  29. Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol. 2005;96(7):946–51.

    Article  CAS  PubMed  Google Scholar 

  30. Yano Y, Hoshide S, Ishikawa J, Hashimoto T, Eguchi K, Shimada K, et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertens Greenwich Conn. 2007;9(10):775–82.

    Article  CAS  Google Scholar 

  31. Looker HC, Krakoff J, Funahashi T, Matsuzawa Y, Tanaka S, Nelson RG, et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab. 2004;89(8):4010.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a intramural grant from JIPMER, Puducherry to the corresponding author.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Medicine and Nephrology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605006, India

    Ramalingam Mageswari, M. G. Sridhar, H. Nandeesha, Sreejith Parameshwaran & K. V. Vinod

Authors
  1. Ramalingam Mageswari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. G. Sridhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Nandeesha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sreejith Parameshwaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. V. Vinod
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. G. Sridhar.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mageswari, R., Sridhar, M.G., Nandeesha, H. et al. Irisin and Visfatin Predicts Severity of Diabetic Nephropathy. Ind J Clin Biochem 34, 342–346 (2019). https://doi.org/10.1007/s12291-018-0749-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-018-0749-7

Keywords

Search

Navigation